Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high-risk populations: A systematic review and meta-analysis

So-Jung Shim1 | Mei Chan1,2 | Louisa Owens1,2 | Adam Jaffe1,2 | Bernadette Prentice1,2 | Nusrat Homaira1,2

1Discipline of Pediatrics, School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
2Respiratory Department, Sydney Children’s Hospital Randwick, Sydney, New South Wales, Australia

Correspondence
Nusrat Homaira, Discipline of Pediatrics, School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Email: n.homaira@unsw.edu.au

Abstract

Background: Oseltamivir is recommended in the treatment of influenza illness in high-risk populations, including those with chronic heart and lung diseases.

Objectives: We conducted a systematic review and meta-analysis to determine the rate of use and effectiveness of oseltamivir in these groups of patients.

Methods: The protocol for the systematic review was registered on PROSPERO (CRD42019125998). Medline, EMBASE, Cochrane CENTRAL, and CINAHL were searched for observational studies and randomized controlled trials published up to 16 February 2020. Quality appraisal of final studies was conducted using GRADE guidelines. Data were extracted using a predeveloped template. Main outcomes measured included the rate of use of oseltamivir for influenza-like-illness and its effectiveness in reducing disease severity in patients with cardiopulmonary diseases. Outcomes measured for effectiveness were influenza-related complications (respiratory infections and asthma exacerbations), hospitalization rates, and time to freedom from illness. Risk of bias was assessed using Cochrane’s Risk of Bias 2.0 tool for randomized trials and Cochrane’s Risk of Bias in nonrandomized Studies of Interventions tool for nonrandomized trials. Where data were available, pooled analyses were conducted. Dichotomous variables were evaluated using the Mantel-Hansel method. A random effect model was applied. Summary measures were reported as risk ratios where relevant.

Results: Our systematic review identified nine studies. Oseltamivir use ranged from 25% to 100%. When oseltamivir group was compared to placebo, rates of respiratory tract infections reduced by 28% (RR = 0.72, 95% CI = 0.59-0.90), hospitalization reduced by 52% (RR = 0.48, 95% CI = 0.28-0.80) and median time to illness alleviation decreased by 10.4 to 120 hours. There was no significant reduction in asthma exacerbation rates.

Abbreviations: CI, confidence interval; ICD-9-CM, international classification of disease, ninth revision, clinical modification; ICU, intensive care unit; ILI, influenza-like illness; RR, risk ratio; WHO, World Health Organization.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC.

https://doi.org/10.1002/hsr2.241
Conclusions: Our systematic review suggests that the use of oseltamivir is beneficial in reducing disease severity, however, its use in high-risk population remains suboptimal.

KEYWORDS
heart diseases, human, influenza, lung diseases, oseltamivir

1 | INTRODUCTION

Influenza is a significant contributor to the global burden of disease causing severe illness in an estimated 3 to 5 million people\textsuperscript{1} and 291,243 to 645,832 respiratory deaths globally annually due to influenza-related complications.\textsuperscript{2} Certain populations are at increased risk of complications due to influenza infection, including individuals under the age of 5, over the age of 65, people with medical conditions, including cardiac and respiratory disease, and pregnant women.\textsuperscript{3,4} Patients with chronic respiratory conditions are particularly at increased risk of influenza-related hospitalizations, need for intensive care unit (ICU) admission and ventilation when compared to those without such conditions.\textsuperscript{5} Influenza infection has also been associated with exacerbation of underlying respiratory diseases such as asthma and cystic fibrosis.\textsuperscript{6,7} Furthermore, in patients with cardiac disease, there is at least two to five times increased risk of mortality from influenza.\textsuperscript{5}

Currently, antiviral medications are the only treatment available for influenza infection. There are three classes of antiviral drugs that target influenza: the adamantanes (matrix-2 [M2]-ion channel inhibitors), neuraminidase inhibitors, and most recently, the selective inhibitor of influenza-cap dependent endonuclease which is currently only approved for use in the United States of America (USA) and Japan. The adamantanes are no longer first-line treatment for influenza due to the increasing development of resistance to these antivirals.\textsuperscript{8} Neuraminidase inhibitors such as zanamivir (Relenza) and oseltamivir (Tamiflu) are more widely prescribed in the treatment of influenza.

Although in 2017, the World Health Organization (WHO) downgraded oseltamivir from a “core” drug to a “complementary” drug in its list of essential medicines\textsuperscript{9} based on the unclear evidence around the effectiveness of oseltamivir, it is recommended that oseltamivir or zanamivir is used empirically in high-risk populations with influenza-like illness (ILI), even when presenting with uncomplicated disease.\textsuperscript{3}

Oseltamivir is the drug of choice for the treatment of influenza for people aged ≥1 year due to its easy oral administration whereas zanamivir is recommended for people aged >5 years which is administered through intravenous route or inhalation.\textsuperscript{3} Oseltamivir is generally well tolerated and safe for use in both adults and children, with some side effects.\textsuperscript{10} Oseltamivir use is recommended within 48 hours of symptom onset in the patient, however, multiple studies have reinforced that earlier administration of oseltamivir results in better outcomes.\textsuperscript{11-13}

Despite being recommended for use in ILI, rates of use of oseltamivir often remain suboptimal. Prior to the 2009 H1N1 influenza pandemic, antiviral prescribing rates in hospitalized patients were less than 30%.\textsuperscript{14} However, during the 2009 H1N1 influenza outbreak, prescribing rates exceeded 80% in hospitalized patients.\textsuperscript{14} More recent data from the 2012 to 2013 influenza season from outpatient care settings showed that <20% of high-risk patients for whom antiviral treatment was appropriate were actually prescribed antiviral medication, with particularly low prescription rates in children.\textsuperscript{15}

Previous studies on the effectiveness of oseltamivir have generally focused on healthy adults and children, with very few studies in high-risk populations, especially children. Given the increased susceptibility of patients with cardiopulmonary conditions to influenza complications, research on the effectiveness of oseltamivir in this specific population may help in guiding clinical practice regarding the use of oseltamivir in this population presenting with ILI.

We conducted a systematic review and meta-analysis to ascertain the rate of oseltamivir use and its effectiveness in people of all ages with cardiopulmonary conditions.

2 | METHODS

2.1 | Protocol and registration

The protocol for the systematic review was registered on PROSPERO (CRD42019125998).

2.2 | Eligibility criteria

Study types: Randomized controlled trials and observational studies (including case-control studies, cross-sectional studies, longitudinal studies, and cohort studies) published up to 16 February 2020 were included. No publication restrictions were imposed. Only papers published in English language were included in the search.

Study participants: Study participants were people of any age with a chronic lung or cardiac disease (including asthma, cystic fibrosis, bronchopulmonary dysplasia, and coronary artery disease) with influenza or ILI.

Study intervention: The intervention was the use of oseltamivir for influenza or ILI in people with chronic lung or cardiac diseases. The comparison group was people with chronic lung or cardiac diseases who did not receive oseltamivir for influenza or ILI.
2.3 | Outcome measures

Outcomes measured were the rate of use and the effectiveness of the intervention. We determined the rate of use as the rate of prescription of oseltamivir in patients with cardiopulmonary conditions. Effectiveness of oseltamivir was determined as the effect on severity of illness (measured as area under the symptom curve), rates of hospitalization, asthma exacerbations, respiratory tract complications such as tracheitis, bronchitis, pneumonia, nasosinusitis, and pharyngitis, and time to alleviation of illness measured in hours. Time to alleviation was defined differently in different studies as median or mean time to resolution of fever (temperature <37.2 °C) and symptoms (chills and myalgia).

2.4 | Information sources

Extensive search using predefined Medical Subject Heading (MeSH) terms (Appendix) was conducted in Medline, EMBASE, CINAHL, and Cochrane Controlled Register of Trials (CENTRAL). MeSH terms used include: “chronic lung disease,” “asthma,” “cystic fibrosis,” “lung dysplasia,” “heart disease” and restricted to “oseltamivir,” “Tamiflu,” “influenza,” and “influenza-like-illness.”

2.5 | Study selection

Records generated by the literature search were managed using EndNoteX9.6 Once duplicates were removed, secondary articles such as systematic reviews, literature reviews, meta-analyses, case reports, and conference abstracts were excluded based on screening of the titles. Abstracts of all remaining articles were then screened based on PICO criteria. The full text of the remaining articles was assessed based on predetermined eligibility criteria.

The reference lists of pertinent systematic reviews and meta-analyses identified in the search as well as reference lists of articles were also searched for relevant studies.

One reviewer (SS) conducted the initial search and screening of articles. Any ambiguities in study selection were resolved by discussion with another reviewer (NH).

2.6 | Data collection process

Data from the systematic review were extracted using predeveloped data extraction template (Table A2). The following information was extracted from eligible studies: study duration, study design, number of participants in the study with cardiopulmonary conditions, age range of participants, clinical setting, inclusion and exclusion criteria, rate of oseltamivir prescription, method of confirmation of influenza infection, timeframe of treatment initiation, dosage of treatment administered and outcomes measured (Tables 1 and 2).

2.7 | Risk of bias assessment

Risk of bias in selected randomized trials was assessed using Cochrane’s Risk of Bias 2.0 tool.17 Risk of bias in nonrandomized studies was assessed with Cochrane’s Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool.16 Overall risk of bias was deemed high if there was high risk of bias in ≥1 domain (confounding bias, selection of participants into the study, classification of interventions, deviations from intended interventions, incomplete outcome data, measurement of outcomes, and selective reporting within the studies), unclear if there was unclear risk of bias in ≥1 domain and low if there was low risk of bias across all six domains.

The quality of evidence across the different outcomes assessed in the systematic review was graded using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines.19 The certainty of the evidence behind each outcome was assessed based on the study designs, risk of bias, inconsistency, indirectness, imprecision, publication bias, and participant size. Based on these factors, the overall quality of evidence was deemed very low, low, moderate, or high. The GRADEpro guideline development tool software was used to assist the synthesis of this data.20 Risk of publication bias was assessed qualitatively as part of the quality of evidence assessment. Quantitative assessment of publication bias was also carried out using funnel plots.

2.8 | Synthesis of results and meta-analysis

The main findings were summarized in a tabular format and a qualitative narrative synthesis of the results was undertaken. Meta-analyses were performed to pool data from studies with sufficient information of the same outcome measures. Dichotomous data were analyzed using risk ratio (RR) and continuous outcomes were analyzed using weighted mean difference (MD). DerSimonian and Laird’s random effects model was used to estimate the overall effect size with 95% confidence interval (CI). For continuous data, missing standard deviations were estimated from other summary statistics such as confidence intervals, standard errors, t values or P values. In studies where these values were missing, the corresponding authors were contacted and values reported as ranges. All statistical analyses were carried out using Review Manager (RevMan) software version 5.3.

3 | RESULTS

3.1 | Study selection

The search generated 330 citations. After removing duplicates and studies that did not meet the eligibility criteria, 29 studies were assessed in full length. One study was excluded based on English language restriction.21 The reference lists of these studies were screened for additional studies and yielded three additional studies. The corresponding authors for two studies on effectiveness were
| Author (year) | Country, years | Study type, design | Study size | Age of participants | Clinical setting | Inclusion criteria | Exclusion criteria | Rate of use (%) | Time to treatment initiation from symptom onset |
|--------------|----------------|-------------------|------------|---------------------|-----------------|-------------------|-------------------|-----------------|-----------------------------------------------|
| Al Subiae (2012) | Saudi Arabia, July to December 2009 | Prospective cohort study | 14<sup>a</sup> | 0 to 12 years | University hospital in Saudi Arabia | Children (aged 0-12 years) who required hospitalization due to confirmed influenza A (H1N1)<sup>a</sup> | | 14<sup>a</sup> | Not stated |
| Bueno (2013) | Madrid, September 2010 to June 2012 | Retrospective study | 83<sup>a,b</sup> | 0 to 13 years | 10 public hospitals in Madrid | Children (0-13 years) hospitalized with influenza-confirmed infection<sup>c</sup> | Risk factors for serious disease (not including asthma), nosocomial influenza infections, ICU admissions direct from emergency department, treatment after 48 hours of admission | 34 | Within 48 hours of admission |
| Coffin (2011) | USA, October to April 2001 to 2007 | Retrospective cohort study | 228<sup>e</sup> | 0 to 21 years | Intensive care unit (ICU) of 41 pediatric hospitals in USA | Children admitted to an ICU for treatment of influenza | Antiviral medication other than oseltamivir, hospitalisation in previous 14 days | 56<sup>e</sup> | Within 24 hours of admission |
| Piedra (2009) | MarketScan databases (Thomson Reuters, Cambridge, MA) from six influenza seasons (October 1-March 31) 2000 to 2006 | Retrospective study | 4550 | 0 to 17 years | Outpatient prescription data | Children and adolescents at high risk of influenza complications | Pneumonia diagnosis, hospitalised or residing in long-term care facility | 1401<sup>e</sup> | Within 1 day after influenza diagnosis |

<sup>a</sup>No separate data for children with CLDs, however, there was sub-group data for children with asthma which has been used here.

<sup>b</sup>Total number of children involved in the study was 287, however, children with a history of asthma was 83.

<sup>c</sup>The inclusion criteria was children without any underlying conditions but asthma was not considered an exclusion criteria, so sub-group data on children with a history of asthma were available.

<sup>d</sup>Criteria for treatment varied between hospitals (some hospitals had ALL hospitalised children treated, others only with risk factors).

<sup>e</sup>This data represents the sub-group data cardiac conditions and respiratory conditions.
### TABLE 2  Characteristics of studies included to evaluate the effectiveness of oseltamivir

| Author (year) | Country, years | Study type, design | Study size | Age of participants | Clinical setting | Inclusion criteria | Exclusion criteria | Intervention | Control | Outcomes | Confirmation of influenza infection | Treatment initiation | Treatment |
|---------------|----------------|-------------------|------------|---------------------|-----------------|------------------|-------------------|--------------|---------|----------|-----------------------------------|---------------------|-----------|
| Johnston (2005) | Multinational study over two influenza seasons (1998-1999) | Randomized, double blind, placebo-controlled | 335 | 6 to 12 years | Multicentre | Asthmatic children (6-12 years), able to perform pulmonary function tests | Positive for respiratory syncytial virus, taking immunosuppressive medication (excluding steroids for asthma treatment), other uncontrolled medical condition, undergone antiviral treatment of influenza in previous 2 weeks | ITTI: n = 84 Per protocol: n = 73 | ITTI: n = 95 Per protocol: n = 89 | Primary: time to freedom from illness Secondary: area under the symptom score-hour curve, proportion of patients with asthma exacerbations, changes in forced expiratory volume at 1 second | Serum influenza antibody titres and swabs for influenza viral culture | Within 48 hours of symptom onset | Oseltamivir 2 mg/kg twice daily as syrup OR placebo |
| Kaiser (2003) | Multicentre phase 3 trials in Northern and Southern Hemisphere influenza seasons from 1997 to 2000 | Randomized, double-blind, placebo-controlled | 769 | Older than 12 | Multicentre | Healthy unimmunized adults and adolescents (13-64 years), at-risk patients (people 65 years or older and adults and adolescents with respiratory and/or cardiac conditions requiring regular outpatient care) | | 137 | 157 | Primary: occurrence of lower respiratory tract complications requiring antibiotic intervention Secondary: hospitalizations, upper respiratory tract complications, overall antibiotic use | Virus isolation from nose and throat swabs or fourfold (or greater) rises in antibody titres | Within 36 hours of symptom onset | Oseltamivir 75 mg twice daily for 5 days OR placebo twice daily for 5 days |
| Lin (2006) | China, flu season of 2002 to 2003 | Randomized, open-label, controlled trial | 56 | Not stated | Nine university tertiary teaching hospitals in China | Patients with chronic respiratory diseases or chronic cardiac disease with confirmed influenza infection | Patients with high suspicion of bacterial infection, pregnant or nursing women, patients with history of alcohol or drug abuse, patients vaccinated for influenza within 12 months prior to start of study | ITT: 27 | ITT: 29 | Primary: duration and severity of illness Secondary: incidence of complications, antibiotic use, hospitalization and total medical cost | Virus isolation and serological analysis | Within 48 hours of illness onset | Oseltamivir 75 mg oral oseltamivir twice a day for five consecutive days OR routine symptomatic treatment in control group |

(Continues)
| Author      | Country, years | Study type, design          | Study size | Age of participants | Clinical setting | Inclusion criteria                                      | Exclusion criteria                                         | Intervention | Control | Outcomes                          | Confirmation of influenza infection | Treatment initiation | Treatment |
|-------------|----------------|-----------------------------|------------|---------------------|------------------|--------------------------------------------------------|-----------------------------------------------------------|--------------|---------|-----------------------------------|------------------------------------|-----------------------|-----------|
| Martin      | -              | Randomized, placebo-        | 402        | 13 to 88 years      | Two centres      | Patients with chronic cardiac and/or respiratory disease with confirmed influenza infection | ITT: 199                                                | ITT: 203     |         | Duration of febrile illness, fever and other symptoms, viral shedding and complications | Positive virus culture or fourfold (or greater) rise in antibody titre | Within 36 hours of onset of influenza symptoms | Oseltamivir 75 mg twice daily for 5 days OR placebo twice daily for 5 days |
| Piedra      | Same as in Table 1 above | Same as in Table 1 above | 1634       | Same as in Table 1 above | Frequencies of pneumonia, respiratory illnesses other than pneumonia, otitis media, and hospitalisation |
| Singh       | Multicentre    | Pooled RCT                  | 251        | 13 to 97 years      | Adolescents and adults (13-97 years) with chronic respiratory and/or cardiac conditions presenting within 36 hours of influenza symptoms | Patients with clinically important chronic illness, known HIV infection, receiving immunosuppressants, history of alcohol or drug abuse, hospitalized | No subgroup data available | Primary: time to alleviation of a seven-symptom cluster | Virus isolation of haemagglutination inhibition (HAI) antibody titration of baseline and convalescent serum samples | 36 hours of symptom onset | Oseltamivir 75 mg twice daily for 5 days OR placebo twice daily for 5 days |

Abbreviations: ITT, intention-to-treat; ITTI, intention-to-treat infected.

335 subjects were enrolled, one subject did not receive the study drug.

769 represents “at-risk” population which encompasses people with chronic cardio-pulmonary disease and/or elderly individuals ≥65y as there is no subset data available specific to people with chronic cardio-pulmonary disease.

Subgroup data of patients with chronic respiratory and/or cardiac disease.

No subgroup data for children with cardio-pulmonary diseases available to determine effectiveness outcomes so these values include children with ALL chronic medical conditions.
contacted to obtain subset data specific to oseltamivir effectiveness in our high-risk populations, however, these data could not be obtained.22,23 Nine studies were included in the final analysis. One study had data on both effectiveness and rate of use of oseltamivir (Figure 1).

3.2 | Participant characteristics

All the studies \( n = 4 \) included to determine the rate of use of oseltamivir were conducted in patients aged <21 years. In the studies \( n = 6 \) included to determine the effectiveness of oseltamivir, two were in children ranging from 1 to 17 years old,11 one did not state age range,25 and the remaining three studies were in participants older than 12 years old.

All the studies in our systematic review included broad populations, and so subset data on people with cardio-pulmonary conditions were extracted according to our predetermined inclusion criteria. The subset data from three studies were from patients with asthma,11,26,27 and two were from those with cardio-pulmonary conditions.25,28 Two studies defined their high-risk population as those with chronic cardio-pulmonary conditions and/or the elderly and as individual data were not available, the whole population was included.30,31 In one study which included patients with any medical conditions, subset data could not be extracted and thus all participants were included as the majority of this population (85.0%) had cardio-pulmonary conditions.29

3.3 | Study characteristics

All four studies on the use of oseltamivir were observational studies, three being retrospective27-29 and one being prospective23 (Table 1). One study included ambulatory patients,29 two included hospitalized patients26,27 and one included patients admitted to ICUs.28 Two of the studies only included patients prescribed oseltamivir within
24 hours of symptoms onset, one study was within 48 hours of symptoms onset and the fourth study did not state treatment initiation in relation to symptom onset. All four studies were in patients with confirmed influenza infection. Influenza infection was confirmed through reverse transcriptase polymerase chain reaction (RT-PCR) or based on ICD-9-CM diagnostic codes of influenza.

Four of the six studies on effectiveness were randomized, double-blind, placebo-controlled multicentre trials (Table 2). One study was a randomized open-label trial. A retrospective study included to evaluate oseltamivir’s effectiveness was also used to determine its rate of use. One study included patients prescribed oseltamivir within 24 hours of influenza diagnosis, two studies included patients prescribed oseltamivir within 48 hours of symptom onset and three studies were patients within 36 hours of symptom onset. All studies on effectiveness were also in patients with confirmed influenza infection. Five studies confirmed influenza infection based on virus isolation from patient swabs and/or rises in serum influenza antibody titers while one study confirmed influenza based on ICD-9-CM diagnostic codes for influenza.

### 3.4 Rates of use of oseltamivir

Rates of oseltamivir use varied between the four different studies from 25% to 100% (Table A1). Two studies were based on data from the USA and had prescribing rates of 25% and 31%. Subset data for people with chronic cardiac or respiratory disease were taken from these studies as their study populations were broader than required by our study. The study conducted in hospitals in Spain had 41% usage rate while Saudi Arabia had 100%. The subset data used from these two studies relevant to our inclusion criteria were patients with asthma.

### 3.5 Effectiveness of oseltamivir

Meta-analysis of the data suggests administration of oseltamivir for the treatment of confirmed influenza infection in patients with cardiopulmonary conditions compared to placebo reduced hospitalization rates significantly (RR = 0.48, 95% CI = 0.28-0.80, I² = 0%, Figure 2A).
Rates of respiratory complications were also significantly less likely when comparing the two groups (RR = 0.72, 95% CI = 0.59-0.90, 6908 patients, I² = 44%, Figure 2B). There was no significant difference in rates of asthma exacerbations between the treatment and control group (RR = 0.63, 95% CI = 0.35-1.12, 680 patients, I² = 0%, Figure 2C). The absolute values, however, suggest a trend favoring oseltamivir when compared to control.

Due to heterogeneity of data and inability to obtain subset data, a pooled analysis to determine time to alleviation of illness and severity of illness could not be performed. However, the absolute values indicated a reduction in the time taken to illness alleviation and reduced severity of illness.11,22,25,31 Time to alleviation of illness ranged between 37.9 to 148.8 hours in the oseltamivir group and 40.8 to 268.8 hours in the placebo group (Figure 3A). The severity of illness was based on the area under curve symptom score in one study25 and the area under the symptom score-hour curve in the second study.11 The severity of illness scores ranged from 817.1 to 1543.3 in the oseltamivir group and 1435 to 1731.3 in the placebo group, indicating greater severity of illness in placebo group (Figure 3B).

3.6 | Risk of bias within studies

There were five randomized controlled studies of which three had high overall risk of bias and two had unclear risk of bias (Figure A1). Four nonrandomized studies had overall unclear risk of bias (Figure A2). Risk of publication bias was deemed high based on qualitative assessment (Table A3) and quantitative evaluation of funnel plots (Figure A3).

3.7 | Overall quality of evidence

The quality of evidence (Table A3) for the duration of illness and respiratory complications outcomes was judged to be high. The quality of evidence for hospitalisation and asthma exacerbation rate were deemed moderate while the certainty assessment for severity of illness outcome was low.

4 | DISCUSSION

Our systematic review demonstrated that rates of oseltamivir use in people with cardio-pulmonary conditions with influenza are sub-optimal. The two studies from the USA from before the 2009 H1N1 influenza pandemic conducted in high-risk children in both in-patient28 and outpatient29 settings, had similar usage rates (25% and 31%). In contrast, the study which included hospitalized children with asthma in Saudi Arabia in the 2009 influenza season had an oseltamivir prescription rate of 100%.26 The only study with post-2009 pandemic data included in the systematic review had prescription rates of 41% in children with asthma in Spain (2010-2012).27 As the rate of use ranged between 20% and 40% outside of the pandemic years, it is possible that the high usage rate during the 2009 influenza26 season may have been due to the perceived risk associated with pandemic influenza leading to the implementation of pandemic strategies, making that year an outlier compared to usual prescribing practices.

Low rate of use could be associated with laboratory testing for influenza. Influenza is not routinely tested for and the lack of confirmatory laboratory data may impact the decision in prescribing oseltamivir despite its recommendation for empirical use in ILI.3,23 The low usage rate may also be due to lack of data on its effectiveness, particularly regarding the target populations who would benefit most from treatment.23 Recent systematic reviews in both adult22 and paediatric23 non high-risk populations have indicated modest benefit with oseltamivir. However, these studies were not in high-risk populations for whom oseltamivir use is recommended by the WHO and for whom treatment may yield a greater benefit when compared to the general population. On the other hand, our systematic review which included only high-risk patients suggests that oseltamivir was

FIGURE 3  Effectiveness of oseltamivir in reducing, A, time to alleviation of illness (hours), b, severity of illness in people with cardiopulmonary disease who were prescribed oseltamivir compared to those who were not
effective in reducing rates of hospitalization and respiratory complications in people with chronic cardiopulmonary disease who were prescribed oseltamivir when compared to those who were not. Our analysis suggests that despite the sub-optimal use, oseltamivir is effective in improving health outcomes in this high-risk population.

Our study demonstrated a 52% reduction in hospitalization rates and a 28% reduction in rates of respiratory tract infections in oseltamivir treated group when compared to placebo in patients with chronic cardiopulmonary disease. We also found that there was a trend suggesting that oseltamivir is effective in reducing the likelihood of asthma exacerbation. These three outcomes are generally indicators of a more severe clinical picture due to influenza infection, suggesting that oseltamivir use in these situations should be indicated to reduce morbidity in high-risk patients.

Other studies have reported variable rates of effectiveness across these outcomes, such as a 34% reduction reported in otitis media incidence in children. This is in contrast to another systematic review which found no significant reduction in hospitalization rates, bronchitis, sinusitis, and otitis media in adults and children. However, these studies again did not focus on the high-risk population for whom use is particularly recommended and could have higher beneficial impact.

Due to a lack of specific data in the studies which we required to conduct analysis, we could not perform meta-analysis for two outcomes: duration of illness and severity of illness. Based on the available data, however, our systematic review found oseltamivir reduced duration of illness by 10.4 to 120 hours in the chronic cardiopulmonary population which suggests that there was a trend favoring a reduced illness duration. Other systematic reviews in the pediatric population without chronic conditions reported a similar reduction of 17.6 hours (CI 95% = 0.62-34.7 hours) and 29 hours (CI 95% = 12-47 hours).

Similarly, we found that there was a trend in our data to show that the severity of illness was reduced in the oseltamivir group when compared with placebo.

### 4.1 Strengths and limitations

Our study is a comprehensive updated synthesis of available data on the use and effectiveness of oseltamivir in high-risk population. This review evaluated the effectiveness of oseltamivir across multiple health outcomes relevant to decision making factors for clinicians.

Our study was limited to studies published in English, however, there was only one study excluded due to this language restriction. Despite extensive search strategy, there were only a few publications eligible for analysis, limiting the power of synthesized results. This highlights the need for more research in this specific population.

There was heterogeneity across the studies in terms of the study populations and study setting which limited pooled analysis of two of the health outcomes. In addition, the studies included in our systematic review had varied definitions of respiratory complications, we combined the upper and lower respiratory tract infections to standardize the outcome, which previous studies have also done. Despite each study having different parameters to define influenza-related complications, oseltamivir demonstrated benefits over no treatment in reducing influenza associated complications including pneumonia and otitis media.

While some studies were focused on specific populations, others were very broad and subset data could not be obtained to quantitatively assess effectiveness for these studies. For instance, Johnston was focused on children with asthma, while Kaiser’s “at-risk” population included both elderly patients and/or people with cardiopulmonary disease, while Piedra included children with all chronic medical conditions in analyses for effectiveness. However, despite these variances, oseltamivir had improved outcomes when compared to control, suggesting a trend toward effectiveness.

In conclusion, our systematic review and meta-analysis suggest oseltamivir is effective in reducing the severity of influenza illness in people with chronic cardio-pulmonary disease, however, the rates of oseltamivir use in this high-risk population are well below WHO recommendations. Further well-designed studies evaluating the effectiveness and investigating the barriers to use of oseltamivir in high-risk population are needed to better guide clinical management of influenza illness.

### ACKNOWLEDGMENT

We would like to extend our utmost gratitude to the respiratory team at the Sydney Children’s Hospital for their support. This work was supported by The Rotary Club of Sydney Cove. The funding organization had no role in the study design, analyses or drafting of the manuscript. NH is funded through NHMRC research fellowship (APP1158646).

### CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

### AUTHOR CONTRIBUTIONS

Conceptualization: Mei Chan, Louisa Owens, Adam Jaffe, Bernadette Prentice, Nusrat Homaira

Data curation: So-Jung Shim

Formal analysis: So-Jung Shim, Mei Chan

Investigation: So-Jung Shim

Methodology: So-Jung Shim, Mei Chan, Louisa Owens, Adam Jaffe, Bernadette Prentice, Nusrat Homaira

Project administration: Mei Chan, Louisa Owens, Adam Jaffe, Bernadette Prentice

Supervision: Bernadette Prentice, Nusrat Homaira

Validation: Mei Chan, Louisa Owens, Adam Jaffe, Bernadette Prentice, Nusrat Homaira

Visualization: So-Jung Shim

Writing—Original Draft Preparation: So-Jung Shim, Nusrat Homaira

Writing—Reviewing & Editing: Mei Chan, Louisa Owens, Adam Jaffe, Bernadette Prentice, Nusrat Homaira

All authors have read and approved the final version of the manuscript.

Nusrat Homaira had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.
**TRANSPARENCY STATEMENT**

Nusrat Homaira affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

**DATA AVAILABILITY STATEMENT**

Data available on request due to privacy/ethical restrictions. Please contact corresponding author to request data.

**ORCID**

So-Jung Shim https://orcid.org/0000-0002-7322-8925
Nusrat Homaira https://orcid.org/0000-0003-3341-7964

**REFERENCES**

1. WHO. Ask the expert: Influenza Q&A; 2018. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-1300.
3. WHO. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. 2010.
4. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917-1930.
5. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
6. Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest. 2010;137(4):852-860.
7. Somayaji R, Goss CH, Khan U, Neradilek M, Neuzil KM, Ortiz JR. Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study. Clin Infect Dis. 2017;64(12):1760-1767.
8. Fiore AE, Fry A, Shay D, Gubareva L, Belshe RS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). Control CID. Contract No.: 1; 2011.
9. Kmieciak Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ. 2017;357:j2841.
10. Dukutowski R. Oseltamivir in seasonal influenza: cumulative evidence in low-and high-risk patients. J Antimicrobial Chemother. 2010;65(2):ii11-ii24.
11. Johnston SL, Ferrero F, Garcia ML, Dukutowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24(3):225-232.
12. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. New Engl J Med. 2009;361(20):1935-1944.
13. Aoki F, Macleod M, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrobial Chemother. 2003;51(1):123-129.
14. Hersh AL, Herigon JC, Ampeko K, Pavia AT, Newland JG. Rapid increase in use of antiviral therapy for hospitalized children with influenza during the 2009 H1N1 epidemic. Pediatr Infect Dis J. 2011;30(10):895-897.
15. Havers F, Thaker S, Clipvard JR, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012–2013 influenza season. Clin Infect Dis. 2014;59(6):774-782.
16. The EndNote Team. EndNote. In: EndNote X9 edn. Philadelphia, PA: Clarivate Analytics; 2013.

17. Sterne J, Savović J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:k4898.
18. Sterne J, Hernán M, Reeves B, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2020;355:h4919.
19. Schünemann H BJ, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html
20. McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. Evidence Prime, Inc; 2015.
21. Fan HW, Han Y, Liu W, et al. A randomized controlled study of oseltamivir and placebo in patients with mild influenza. Zhonghua Nei Ke Za Zhi. 2019;58(8):560-565.
22. Singh S, Barghoorn J, Bagdonas A, et al. Clinical benefits with oseltamivir in treating influenza in adult populations. Clin Drug Invest. 2003;23(9):561-569.
23. Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395(10217):42-52.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
25. J-t L, X-z Y, D-j C, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006;22(1):75-82.
26. Al Subaie SS, Al Saadi MM. Features associated with severe disease in hospitalized children with 2009 influenza A (H1N1) infection at a university hospital in Riyadh, Saudi Arabia. Ann Saudi Med. 2012;32(1):53-58.
27. Bueno M, Calvo C, Méndez-Echevarría A, et al. Oseltamivir treatment for influenza in hospitalized children without underlying diseases. Pediatr Infect Dis J. 2013;32(10):1066-1069.
28. Coffin SE, Leckerman K, Keren R, Hall M, Localio R, Zaoutis TE. Oseltamivir shortens hospital stay of critically ill children hospitalized with seasonal influenza: a retrospective cohort study. Pediatr Infect Dis J. 2011;30(11):962-966.
29. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124(1):170-178.
30. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14):1667-1672.
31. Martin C, Mahoney P, Ward P, eds. Oral Oseltamivir Reduces Febrile Illness in Patients Considered at High Risk of Influenza Complications. International Congress Series. Vol 1219, pp. 807-811. Elsevier; 2001.
32. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965.
33. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley R, Monto AS. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis. 2017;66(10):1492-1500.
34. Martinue AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.
APPENDIX A: MESH TERMS USED FOR CINAHL, CENTRAL, MEDLINE AND EMBASE

CINAHL:
01. Chronic lung disease
02. Chronic cardiac disease
03. Asthma
04. Cystic fibrosis
05. Oseltamivir
06. Tamiflu
07. Influenza
08. (S1 or S2 or S3 or S4) AND (S5 or S6) AND S7

CENTRAL:
01. ("chronic lung disease")
02. (chronic cardiac disease)
03. (asthma)
04. (cystic fibrosis)
05. #1 or #2 or #3 or #4
06. (oseltamivir)
07. (Tamiflu)
08. #6 or #7
09. (influenza)

MEDLINE:
01. Lung diseases/
02. Asthma/
03. Cystic fibrosis/
04. Bronchopulmonary dysplasia/
05. Heart diseases/
06. 1 or 2 or 3 or 4 or 5
07. Influenza, human/
08. Oseltamivir/ or oseltamivir.mp. or Tamiflu.mp.
09. 6 and 7 and 8

EMBASE:
01. Chronic lung disease/
02. Asthma/
03. Cystic fibrosis/
04. Lung dysplasia/
05. Heart disease/
06. 1 or 2 or 3 or 4 or 5
07. Oseltamivir.mp. or oseltamivir/ or Tamiflu.mp.
08. Influenza/
09. 6 and 7 and 8

TABLE A1  Rates of oseltamivir prescription reported in four different studies

| Author (year) | Country, years | Oseltamivir (n = sample size) | No-oseltamivir (n = sample size) | Total sample size (n = sample size) | Rate of use (%) |
|---------------|----------------|-------------------------------|---------------------------------|-----------------------------------|----------------|
| Al Subiae (2012)* | Saudi Arabia, July to December 2009 | 14 | 0 | 14 | 100 |
| Bueno (2013)b | Madrid, September 2010 to June 2012 | 34 | 49 | 83 | 41 |
| Coffin (2011)c | USA, October to April 2001 to 2007 | 56 | 172 | 228 | 25 |
| Piedra (2009)c | MarketScan databases (Thomson Reuters, Cambridge, MA) from six influenza seasons (October 1-March 31) 2000 to 2006 | 1401 | 3149 | 4550 | 31 |

*No separate data for people with cardio-pulmonary disease, however, there was sub-group data for those with asthma which has been used here.

bCriteria for treatment varied between hospitals (some hospitals had all hospitalised people treated, others only with risk factors).

cThis data represents the sub-group data for people with cardiac conditions and respiratory conditions.
**TABLE A2**  Predeveloped data extraction template for use of oseltamivir and effectiveness of oseltamivir

| Author (year) | Country, years | Study type, design | Study size | Age of participants | Clinical setting | Inclusion criteria | Exclusion criteria | No-oseltamivir | Rate of influenza use (%) | Confirmation of influenza infection | Treatment initiation | Treatment of oseltamivir group | Treatment of control group |
|---------------|----------------|--------------------|------------|--------------------|------------------|-------------------|------------------|----------------|--------------------------|-------------------------------|----------------|--------------------------|--------------------------|
|               |                |                    |            |                    |                  |                   |                  |                |                         |                               |                 |                         |                          |

For example, double-blind RCT, prospective cohort study

For example, children aged 0 to 17 years

For example, outpatient clinics

For example, 200

For example, 200

For example, within 48 hours of symptom onset

For example, placebo for 5 days

For example, 10 mg morning and night for 5 days

For example, PCR, viral culture

For example, 10 mg morning and night for 5 days

For example, PCR, viral culture

For example, placebo for 5 days

For example, 10 mg morning and night for 5 days

For example, PCR, viral culture

For example, placebo for 5 days
## TABLE A3  Overall quality of evidence across the five outcomes for effectiveness of oseltamivir judged using the GRADEpro tool

| Certainty assessment | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients | Oseletamivir | Control | Certainty |
|----------------------|----------------|--------------|--------------|---------------|--------------|-------------|---------------------|----------------|-------------|---------|-----------|
| **Duration of illness** | 4              | Randomized trials | Not serious<sup>a,b</sup> | Not serious | Not serious | Not serious | Publication bias strongly suspected strong association<sup>c</sup> | >299 days | >321 days | ⊕⊕⊕⊕ | HIGH     |
| **Severity of illness** | 2              | Randomized trials | Not serious<sup>b,e</sup> | Not serious | Not Serious | Serious<sup>f</sup> | Publication bias strongly suspected<sup>f</sup> | 100            | 124        | ⊕⊕      | LOW      |
| **Hospitalisation rate** | 3              | Randomized trials<sup>g</sup> | Not serious<sup>h</sup> | Not serious | Not serious | Not serious | Publication bias strongly suspected<sup>f</sup> | 2029           | 4151       | ⊕⊕⊕      | MODERATE |
| **Asthma exacerbation rate** | 2              | Randomized trials | Not serious | Not serious | Not serious | Not serious | Publication bias strongly suspected<sup>f</sup> | 283            | 297        | ⊕⊕⊕      | MODERATE |
| **Respiratory complications** | 4              | Randomized trials<sup>g</sup> | Not serious | Not serious | Not serious | Not serious | Publication bias strongly suspected strong association<sup>c</sup> | 2370           | 4538       | ⊕⊕⊕⊕     | HIGH     |

<sup>a</sup>Duration of illness is a slightly more subjective outcome to measure (patients made diary entries of symptoms).

<sup>b</sup>Lin, 2005: some concern for bias as study design was open-label, not placebo-controlled or blinded.

<sup>c</sup>Martin, 2001, Kaiser, 2003 and Lin, 2005 were sponsored by Roche—a pharmaceutical company which produces oseltamivir. There were numerous trials on oseltamivir which have not been published, suggesting that its effectiveness may be overpublished.

<sup>d</sup>Sum of the oseltamivir and no-oseltamivir groups for Martin, 2001, Lin, 2005 and Johnston, 2006. No subset data available for Kaiser, 2003 for high-risk population.

<sup>e</sup>Severity of illness is a more subjective outcome to measure.

<sup>f</sup>Not sufficiently large sample size (n < 400).

<sup>g</sup>Majority of articles are randomized controlled trials, but includes one retrospective study (Piedra, 2009) which was assessed for bias using the ROBINS-i tool.

<sup>h</sup>All-cause hospitalization rates were used (there may have been hospitalizations not related to influenza illness.)
**Figure A1**  Risk of bias in randomised trials measuring effectiveness of oseltamivir (based on Cochrane RoB 2.0 tool)

| Study           | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting of outcome data | Other bias |
|-----------------|---------------------------------------------|----------------------------------------|----------------------------------------------------------|-------------------------------------------------|----------------------------------------|------------------------------------|-----------|
| Johnston 2005   | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) |
| Kaiser 2003     | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) |
| Lin 2005        | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) |
| Martin 2001     | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) |
| Singh 2003      | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) | ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) ![Icon](icon1) |

**Figure A2**  Risk of bias in nonrandomized studies measuring the rate of use of oseltamivir (based on ROBINS-I tool)
**FIGURE A3** Funnel plots for: A, Rates of hospitalization, B, Rates of asthma exacerbation, C, Rates of respiratory complications, D, Severity of illness